{"doi":"10.1093/neuonc/noaa016","title":"A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study","abstract":"BACKGROUND: A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series. METHODS: Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity. RESULTS: Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively. CONCLUSION: Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG. TRIAL REGISTRATION: NCT01514201.","journal":"Neuro-Oncology","year":2020,"id":55758,"datarank":2.4035099532313984,"base_score":4.51085950651685,"endowment":4.51085950651685,"self_citation_contribution":0.6766289259775276,"citation_network_contribution":1.726881027253871,"self_endowment_contribution":0.6766289259775276,"citer_contribution":1.726881027253871,"corpus_percentile":null,"corpus_rank":null,"citation_count":90,"citer_count":79,"citers_with_citation_signal":69,"citers_with_endowment":69,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9568,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01514201"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":290378,"name":"Jack M. Su","orcid":null,"position":1,"is_corresponding":false},{"id":288898,"name":"Arzu Onar‐Thomas","orcid":"0000-0003-1005-2413","position":2,"is_corresponding":false},{"id":288899,"name":"Catherine A. Billups","orcid":"0000-0003-2819-4946","position":3,"is_corresponding":false},{"id":5560,"name":"Xiao‐Nan Li","orcid":"0000-0002-6719-3789","position":4,"is_corresponding":false},{"id":260741,"name":"Tina Young Poussaint","orcid":"0000-0002-0814-0791","position":5,"is_corresponding":false},{"id":288900,"name":"Edward R. Smith","orcid":"0000-0002-6317-8450","position":6,"is_corresponding":false},{"id":288901,"name":"Patrick Thompson","orcid":"0009-0003-2666-8359","position":7,"is_corresponding":false},{"id":288902,"name":"Adekunle M. Adesina","orcid":"0000-0003-4013-7741","position":8,"is_corresponding":false},{"id":290379,"name":"Pete Ansell","orcid":null,"position":9,"is_corresponding":false},{"id":290380,"name":"Vincent L. Giranda","orcid":null,"position":10,"is_corresponding":false},{"id":288903,"name":"Arnold C. Paulino","orcid":"0000-0002-0269-3045","position":11,"is_corresponding":false},{"id":288904,"name":"Lindsay Kilburn","orcid":"0000-0003-1478-3619","position":12,"is_corresponding":false},{"id":290381,"name":"Ibrahim Quaddoumi","orcid":null,"position":13,"is_corresponding":false},{"id":284694,"name":"Alberto Broniscer","orcid":"0000-0001-9646-0463","position":14,"is_corresponding":false},{"id":288905,"name":"Susan M. Blaney","orcid":"0000-0002-6194-4799","position":15,"is_corresponding":false},{"id":236601,"name":"Ira J. Dunkel","orcid":"0000-0001-8091-6067","position":16,"is_corresponding":false},{"id":288906,"name":"Maryam Fouladi","orcid":"0000-0002-5693-035X","position":17,"is_corresponding":false},{"id":290377,"name":"Patricia Baxter","orcid":null,"position":0,"is_corresponding":true}],"reference_count":44,"raw_metadata":null,"created_at":"2026-07-18T21:05:29.672878Z","pmid":"32009149","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}